Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) research hub

A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

This study is testing a new medicine, BI 1015550, for people with progressive fibrosing interstitial lung diseases (PF-ILDs). Researchers want to see if it helps improve lung function and is safe to use over about a year.